All patients enrolled in the Sonic II Registry are scheduled for follow-up at 30 days, six months, and one year following the OmniWave procedure. The first patient was enrolled at the Midwest Institute for Minimally Invasive Therapies (MIMIT) in Chicago.
Richard Ganz, president and CEO of OmniSonics, said: “The initiation of the Sonic II Registry is an important strategic development in OmniSonics’s continuation of a strong clinical program to support the OmniWave System as a therapy for treating patients with acute limb ischemia (ALI).”